Centene · MOUD Buprenorphine Subli · Medicaid MCO appeal

MOUD Buprenorphine Subli denied for failing step therapy by Centene?

Q: How long do I have to appeal a Centene MOUD Buprenorphine Subli denial?

Internal appeal window: 60 days from the date on the notice of action. External review window: State fair hearing — request typically within 90 days of the MCO's appeal decision. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-25

Medicaid MCO appeal

Cite: 42 CFR 438 Subpart F

Medicaid Managed Care Organization (MCO) denials are governed by federal Medicaid regulations and your state's Medicaid program rules. You have 60 days from the notice of action to file an internal appeal with the MCO. If the MCO upholds, you can request a state fair hearing — and importantly, you can request "aid pending appeal" (continued coverage during the review) if the appeal is filed within 10 days of the action.

Internal appeal window

60 days from the date on the notice of action

External review window

State fair hearing — request typically within 90 days of the MCO's appeal decision

What Centene typically requires

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

Source policy: Centene/Envolve Medicaid Buprenorphine PA

What works in the appeal

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

The Centene angle on MOUD Buprenorphine Subli

## Why Centene Applies Step Therapy to Sublingual Buprenorphine — and How to Appeal

Centene health plans (including Ambetter, WellCare, and state-specific Medicaid managed care contracts) sometimes impose step-therapy protocols that require a patient to "fail first" on a different MOUD agent — typically oral naltrexone or methadone through an OTP — before approving sublingual buprenorphine. This is clinically controversial: MOUD agents are not interchangeable for every patient, and forcing a step can delay or disrupt treatment for opioid use disorder, a condition where treatment interruption carries serious risk.

Step-therapy denials for MOUD are especially susceptible to appeal because many states have enacted step-therapy reform laws and because federal parity law (the Mental Health Parity and Addiction Equity Act, MHPAEA) limits how plans may impose nonquantitative treatment limitations on substance use disorder benefits.

## Federal and State Legal Protections

MHPAEA parity argument: Centene cannot apply step-therapy requirements to MOUD that are more restrictive than comparable requirements for analogous medical/surgical benefits. Document this argument explicitly.
State step-therapy exceptions: Most states require plans to grant step-therapy exceptions when: (a) the required first-step drug is contraindicated for the patient, (b) the patient already tried and failed or could not tolerate the required agent, or (c) the step would cause a clinically significant delay in needed treatment.
Internal appeal (ACA §2719 / ERISA §503): File within 180 days of the denial; plans must respond within 30 days (pre-service) or 60 days (post-service).
Expedited review: Available within 72 hours if the standard timeline risks serious health jeopardy.
External independent review: If internal appeal fails or the plan misses its deadline, you have approximately four months from the initial denial to initiate external review under ACA §2719.

## The Appeal Process

1. Obtain the full denial letter and identify precisely which step drug the plan requires. 2. Pull Centene's published step-therapy and medical-necessity criteria for this drug. 3. Determine which exception pathway applies to your patient (prior failure, contraindication, or clinical urgency). 4. File a written internal appeal invoking the applicable state exception statute by name. 5. Request external review if the internal appeal is denied.

## Documentation to Gather

Diagnosis confirmation: DSM-5 opioid use disorder diagnosis with date, severity specifier, and treating clinician.
Step-drug history: For each required prior agent — dates of trial, dose range attempted, reason for discontinuation (adverse effect, treatment failure, contraindication), documented in chart notes.
Clinical rationale for buprenorphine specifically: Prescriber letter explaining why buprenorphine is the medically appropriate agent for this individual, referencing ASAM or SAMHSA MOUD guidelines generically.
Parity analysis (if applicable): A statement from the prescriber or attorney noting that the step requirement appears more restrictive than comparable medical/surgical benefit requirements.
FDA prescribing information: Reference that buprenorphine is FDA-approved for this indication and that the step requirement is not reflected in the label's clinical guidance.

## Criteria-Mapping Structure

| Plan Step Requirement | Patient-Specific Response | |---|---| | Trial of [required step drug] | [Dates, doses, documented outcome/failure] | | Exception: contraindication to step drug | [Clinician attestation with chart support] | | Exception: prior treatment failure | [Chart notes, dates, objective outcome data] | | Buprenorphine medically necessary | [Prescriber letter; reference to ASAM guideline framework] |

Address every step criterion in the plan's policy. A well-documented exception letter that maps to the plan's own exception criteria — and invokes parity — wins the majority of these appeals.

Next steps

Look at the date on the "notice of action" — the 60-day clock starts there.
If you file within 10 days, request "aid pending appeal" to keep coverage during the review.
Submit the internal appeal in writing using the form on the MCO's denial letter.
If denied, request a state fair hearing — the form is on your state Medicaid agency's website.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other insurers on MOUD Buprenorphine Subli

Aetna denied for failing step therapy of MOUD Buprenorphine Subli

Other denial reasons for Centene MOUD Buprenorphine Subli

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on 42 CFR 438 Subpart F. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.